[go: up one dir, main page]

AR035456A1 - Compuestos derivados de dihidro-benzo[b][1,4]-diazepin-2-ona , su empleo, un procedimiento para prepararlos y medicamentos que los contienen - Google Patents

Compuestos derivados de dihidro-benzo[b][1,4]-diazepin-2-ona , su empleo, un procedimiento para prepararlos y medicamentos que los contienen

Info

Publication number
AR035456A1
AR035456A1 ARP020101313A ARP020101313A AR035456A1 AR 035456 A1 AR035456 A1 AR 035456A1 AR P020101313 A ARP020101313 A AR P020101313A AR P020101313 A ARP020101313 A AR P020101313A AR 035456 A1 AR035456 A1 AR 035456A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
alkoxy
fluorine
alkyl
cyano
Prior art date
Application number
ARP020101313A
Other languages
English (en)
Inventor
Geo Adam
Erwin Goetschi
Vincent Mutel
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR035456A1 publication Critical patent/AR035456A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos derivados de dihidro-benzo[b][1,4]-diazepin-2-ona de fórmula general (1) en donde R1 es ciano, flúor-alquilo inferior, alcoxilo inferior; flúor-alcoxilo inferior o es pirrol-1-ilo, el cual está sin sustituir o sustituido con uno a tres sustituyentes seleccionados del grupo formado por flúor, cloro, ciano, fenilo, opcionalmente sustituido con halógeno, -(CH2)1-4-hidroxilo, flúor-alquilo inferior, alquilo inferior, -(CH2)n-alcoxilo inferior, -(CH2)nC(O)O-R'', -(CH2)1-4-NR'R'', hidroxi-alcoxilo inferior y -(CH2)n-CONR'R''; R2 es hidrógeno, si R1 es pirrol-1-ilo opcionalmente sustituido, como se ha definido más arriba, o es halógeno, hidroxilo, alquilo inferior, flluór-alquilo inferior, alcoxilo inferior, hidroximetilo, hidroxietoxilo, alcoxilo inferior-(etoxilo)n (n=1 a 4), alcoximetilo inferior, cianometoxilo, morfolin-4-ilo, tiomorfolin-4-ilo, 1-oxotiomorfolin-4-ilo, 1,1-dioxotiomorfolin-4-ilo, 4-oxo-piperidin-1-ilo, 4-alcoxi-piperidin-1-ilo, 4-hidroxi-piperidin-1-ilo, 4-hidroxietoxi-piperidin-1-ilo, 4-alquilo inferior-piperazin-1-ilo, alcoxicarbonilo, 2-alquilamino-etilsufanilo, N,N-bis alquilamino inferior alquilo inferior, carbamoilmetilo, alquilsufonilo, alcoxicarbonilo inferior-alquilo inferior, alquilcarboxi-alquilo inferior, carboxi-alquilo inferior, alcoxicarbonilmetilsulfanilo, carboximetilsulfanilo, 1,4-dioxa-8-aza-espiro[4,5]dec-8-ilo, carboxi-alcoxilo inferior, ciano-alquilo inferior, 2,3-dihidroxi-alcoxilo inferior, carbamoilmetoxilo, 2-oxo-[1,3]-dioxolan-4-il-alcoxilo inferior, N-(2-hidroxi-alquilo inferior)-N-alquilamino inferior, hidroxicarbamoil-alcoxilo inferior, 2,2-dimetil-tetrahidro-[1,3]dioxolo[4-5c]-pirrol-5-ilo, alcoxilo inferior-carbamoilo-alcoxilo inferior, 3R-hidroxi-pirrolidin-1-ilo, 3,4-dihidroxi-pirrolidin-1-ilo, 2-oxo-oxozalidin-3-ilo, alquilo inferior - carbamoilmetoxi, o aminocarbonil-alcoxilo inferior; Y es -CH= o =N-; R3 es halógeno, alquilo inferior, flúor-alquilo-inferior, alcoxilo inferior, ciano, -(CH2)n-C(O)-OR", -(CH2)n-C(O)-NR'R'', o es un heterociclo aromático de cinco miembros opcionalmente sustituido, el cual puede estar sustituido con halógeno, flúor-alquilo inferior, flúor-alcoxilo inferior, ciano, - (CH2)n-NR'R'', -(CH2)n-C(O)-OR'', -(CH2)n-C(O)-NR'R'', -(CH2)n-SO2-NR'R'', -(CH2)n-C(NH2)=NR", hidroxilo, alcoxilo inferior, alquiltio inferior, o con alquilo inferior el cual está opcionalmente sustituido con flúor, hidroxilo, alcoxilo inferior, ciano o carbamoiloxilo, R' es hidrógeno, alquilo inferior, cicloalquilo de C3-6, flúor-alquilo inferior o 2-alcoxilo inferior alquilo inferior; R" es hidrógeno, alquilo inferior, cicloalquilo de C3-6, flúor-alquilo inferior, 2-alcoxilo inferior alquilo inferior, -(CH2)2-4di-alquilamino inferior, -(CH2)2-4-morfolinilo, -(CH2)2-4-pirrolidinilo, -(CH2)2-4-piperidinilo o 3-hidroxi-alquilo inferior; n es 0, 1, 2, 3 o 4; y sus sales de adición farmacéuticamente aceptables. Trastornos neurológicos.
ARP020101313A 2001-04-12 2002-04-10 Compuestos derivados de dihidro-benzo[b][1,4]-diazepin-2-ona , su empleo, un procedimiento para prepararlos y medicamentos que los contienen AR035456A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12

Publications (1)

Publication Number Publication Date
AR035456A1 true AR035456A1 (es) 2004-05-26

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101313A AR035456A1 (es) 2001-04-12 2002-04-10 Compuestos derivados de dihidro-benzo[b][1,4]-diazepin-2-ona , su empleo, un procedimiento para prepararlos y medicamentos que los contienen

Country Status (37)

Country Link
US (1) US6548495B2 (es)
EP (1) EP1379522B1 (es)
JP (1) JP4043953B2 (es)
KR (1) KR100566178B1 (es)
CN (1) CN1268626C (es)
AR (1) AR035456A1 (es)
AT (1) ATE287883T1 (es)
AU (1) AU2002310912B2 (es)
BG (1) BG108253A (es)
BR (1) BR0208887A (es)
CA (1) CA2441771C (es)
CZ (1) CZ20033002A3 (es)
DE (1) DE60202761T2 (es)
DK (1) DK1379522T3 (es)
EC (1) ECSP034796A (es)
ES (1) ES2235044T3 (es)
GT (1) GT200200072A (es)
HR (1) HRP20030791B1 (es)
HU (1) HUP0400991A3 (es)
IL (2) IL158021A0 (es)
JO (1) JO2273B1 (es)
MA (1) MA27011A1 (es)
MX (1) MXPA03009317A (es)
MY (1) MY130369A (es)
NO (1) NO325300B1 (es)
NZ (1) NZ528345A (es)
PA (1) PA8543201A1 (es)
PE (1) PE20021072A1 (es)
PL (1) PL367086A1 (es)
PT (1) PT1379522E (es)
RU (1) RU2270197C2 (es)
SI (1) SI1379522T1 (es)
SK (1) SK13692003A3 (es)
UY (1) UY27259A1 (es)
WO (1) WO2002083665A1 (es)
YU (1) YU79103A (es)
ZA (1) ZA200307242B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60009116T2 (de) 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
SI1651234T1 (sl) * 2003-07-25 2008-02-29 Hoffmann La Roche Kombinacija antagonista mglur2 in inhibitorja ache za zdravljenje akutnih in/ali kronicnih nevroloskih motenj
US7459563B2 (en) 2004-11-05 2008-12-02 Hoffmann-La Roche Inc. Process for the preparation of isonicotinic acid derivatives
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2137167B1 (en) * 2007-04-19 2011-08-10 F. Hoffmann-La Roche AG Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
TWI475995B (zh) 2007-09-14 2015-03-11 Janssen Pharmaceuticals Inc 1’,3’-二取代-4-苯基-3,4,5,6-四氫-2h,1’h-〔1,4’〕聯吡啶基-2’-酮化物
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
AU2008323287B2 (en) 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
RU2015116749A (ru) 2012-10-23 2016-12-20 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения аутических расстройств
BR112015020545A2 (pt) * 2013-02-28 2017-07-18 Eisai R&D Man Co Ltd derivado de tetraidroimidazo[1,5-d][1,4]oxazepina
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3424535A1 (en) 2014-01-21 2019-01-09 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
RU2016144702A (ru) 2014-04-23 2018-05-24 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения интеллектуальной недостаточности
WO2015191630A1 (en) * 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
PL357418A1 (en) * 1999-10-15 2004-07-26 F.Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
DE60009116T2 (de) * 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten

Also Published As

Publication number Publication date
HRP20030791B1 (en) 2006-06-30
NO20034496D0 (no) 2003-10-08
BR0208887A (pt) 2004-06-29
CA2441771A1 (en) 2002-10-24
US6548495B2 (en) 2003-04-15
UY27259A1 (es) 2002-10-31
WO2002083665A1 (en) 2002-10-24
YU79103A (sh) 2006-05-25
PT1379522E (pt) 2005-05-31
GT200200072A (es) 2003-06-19
DE60202761D1 (de) 2005-03-03
CA2441771C (en) 2008-12-30
HUP0400991A2 (hu) 2004-08-30
ATE287883T1 (de) 2005-02-15
NO325300B1 (no) 2008-03-25
DE60202761T2 (de) 2006-01-12
MXPA03009317A (es) 2004-02-12
NO20034496L (no) 2003-10-08
EP1379522B1 (en) 2005-01-26
PE20021072A1 (es) 2002-12-07
DK1379522T3 (da) 2005-05-30
IL158021A0 (en) 2004-03-28
JP4043953B2 (ja) 2008-02-06
RU2270197C2 (ru) 2006-02-20
RU2003130648A (ru) 2005-04-10
CN1268626C (zh) 2006-08-09
HRP20030791A2 (en) 2005-06-30
SI1379522T1 (en) 2005-04-30
MA27011A1 (fr) 2004-12-20
SK13692003A3 (sk) 2004-05-04
MY130369A (en) 2007-06-29
KR20030088502A (ko) 2003-11-19
EP1379522A1 (en) 2004-01-14
BG108253A (bg) 2005-03-31
US20020198197A1 (en) 2002-12-26
HK1068339A1 (en) 2005-04-29
JP2004525965A (ja) 2004-08-26
IL158021A (en) 2010-04-15
CZ20033002A3 (cs) 2004-03-17
ZA200307242B (en) 2004-12-16
KR100566178B1 (ko) 2006-03-29
NZ528345A (en) 2005-04-29
PL367086A1 (en) 2005-02-21
HUP0400991A3 (en) 2009-06-29
AU2002310912B2 (en) 2005-06-16
PA8543201A1 (es) 2002-10-31
JO2273B1 (en) 2005-04-07
ES2235044T3 (es) 2005-07-01
CN1522252A (zh) 2004-08-18
ECSP034796A (es) 2003-12-01

Similar Documents

Publication Publication Date Title
AR035456A1 (es) Compuestos derivados de dihidro-benzo[b][1,4]-diazepin-2-ona , su empleo, un procedimiento para prepararlos y medicamentos que los contienen
AR035816A1 (es) Compuestos derivados de dihidro-benzo[b][1,4]diazepin-2-ona, su uso, un proceso para prepararlos y medicamentos que los contienen.
AR072779A1 (es) Inhibidores macrociclicos de la replicacion del virus de la hepatitis c
CO5200848A1 (es) Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
AR042273A1 (es) Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen
UY26727A1 (es) Derivados de tropano útiles en terapia
ES2668775T3 (es) Compuestos tetracíclicos
CR9690A (es) 3-acilaminobenzanilidas insecticidas
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
ECSP045078A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplásicos
CO5601006A2 (es) Procedimiento para la preparacion de esteres de escopina
AR039554A1 (es) Compuestos derivados de aminopirimidina y aminopiridina, su empleo, un metodo para su preparacion, composiciones que los comprenden, y compuestos intermediarios
AR082888A1 (es) Compuestos de piridina para la inhibicion de nampt
AR002746A1 (es) Compuestos derivados de pirimidina condensados con un anillo heterociclico y composicion farmaceutica conteniendo dichos compuestos.
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR033942A1 (es) Compuestos de monofluoroalquilo aplicables en la potenciacion de los compuestos intermediarios utilizables en la sintesis de dichos compuestos de monofluoralquilo; composiciones farmaceuticas formuladas con dichos compuestos potenciadores y metodos para la potenciacion de las funciones de dichos rec
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR039122A1 (es) Derivados de ftalimido como inhibidores de monoamino oxidasa b
DK290688A (da) Dihydropyridin-forbindelser og deres anvendelse som antiallergiske og antiinflammatoriske midler samt farmaceutiske praeparater indeholdende disse forbindelser
ECSP034619A (es) Derivados de pirimidina
AR057197A1 (es) Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona
CO5630031A2 (es) Derivados de benzotiazol como ligandos del receptor adenosina

Legal Events

Date Code Title Description
FC Refusal
FB Suspension of granting procedure